Pentoxifylline added to methotrexate for rheumatoid arthritis inflammation
Official title: Clinical Study Evaluating the Effect of Pentoxifylline as Anti Inflammatory in Patients With Rheumatoid Arthritis
Run by Tanta University · NCT06998628 · Data updated 2026-11-12
This trial tests whether adding pentoxifylline to standard methotrexate treatment reduces inflammation and improves symptoms in adults with active rheumatoid arthritis.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Damietta, Damietta Governorate) |
| Status | Recruiting |
| Started | June 2, 2025 |
| Main results expected | May 30, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | October 5, 2026 |
| Trial ID | NCT06998628 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–70 years old with active rheumatoid arthritis (DAS28 > 2.6) who are receiving conventional DMARD therapy and do not have contraindicating liver, kidney, bleeding, or pregnancy-related issues are ideal candidates.
✕Probably not a fit
People in remission, those already taking biologic or synthetic DMARDs, pregnant or breastfeeding individuals, or patients with significant hepatic, renal, or bleeding disorders are unlikely to benefit or are not eligible for this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 2 interventional study conducted at Egyptian university sites testing pentoxifylline as an anti-inflammatory adjunct to conventional disease‑modifying therapy (methotrexate) in adults with active rheumatoid arthritis. Eligible participants are adults aged 18–70 with active disease (DAS28 > 2.6) who are already on conventional DMARDs; patients on biologic or synthetic DMARDs, pregnant or lactating individuals, and those with significant liver, kidney, or bleeding disorders are excluded. The study compares clinical disease activity and inflammatory markers over the treatment period to see if pentoxifylline provides additional benefit. Safety and tolerability, including adverse events related to hepatic, renal, or bleeding risks, are monitored throughout the trial.
Why it matters
Potential benefit: If successful, adding pentoxifylline could offer a well‑tolerated, low‑cost oral option to further reduce joint inflammation and improve symptoms when used with methotrexate.
How similar studies have gone: Pentoxifylline has known anti‑inflammatory effects and small prior studies in inflammatory conditions, including limited RA research, suggest possible benefit but the evidence remains inconclusive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) \[9\] i.e., 28 joints disease activity score (DAS 28) \>2.6. * Patients receiving the conventional DMARDs. * Both sexes. * Age range between 18and 70 years old Exclusion Criteria: * Patients with retinal or cerebral hemorrhage. * Patients with renal and hepatic dysfunction. * Patients with hypersensitivity to study medications. * Pregnant and lactating females. * Patients receiving biological or synthetic DMARDs
Where it's running
-
Faculty of Medicine, Al-Azhar University
Damietta, Damietta Governorate, Egypt Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
GenAI-assisted RA bone erosion risk and DMARD choice
This study tests whether GenAI-based decision support can help doctors assess rheumatoid arthritis bone erosion risk and pick DMARDs for newly diagnosed inpatients.
-
Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people
This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.
-
Telitacicept for difficult-to-treat rheumatoid arthritis
This study tests whether adding telitacicept to standard therapy helps adults with hard-to-treat rheumatoid arthritis see better control of their symptoms.
-
PTC844 in people with active rheumatoid arthritis
This study tests whether PTC844 is safe and how it behaves in the body compared with placebo for people with active rheumatoid arthritis.
-
First-in-human test of CND319 in healthy people and people with rheumatic diseases
This early study tests whether CND319 is safe and tolerable and whether it shows any signs of activity in healthy adults and in people with rheumatoid arthritis or Sjogren's syndrome.
-
IV sarilumab for adults with rheumatoid arthritis
This study tests IV sarilumab to see how it works and how safe it is for adults with moderately to severely active rheumatoid arthritis, with or without certain standard arthritis medicines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.